Major Depressive Disorder
1,728
190
237
1,077
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
434 trials with published results (25%)
Research Maturity
1077 completed trials (62% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
5.9%
102 terminated out of 1728 trials
91.3%
+4.8% vs benchmark
26%
445 trials in Phase 3/4
40%
434 of 1077 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1077 completed trials
Clinical Trials (1728)
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Venous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Individualized (fMRI-guided) TMS Treatment for Depression
A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
RECOVERS - Realigning Emotion and COgnition Via prEcision Regulation networkS
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
Natural History of Depression, Bipolar Disorder and Suicide Risk
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
Multimodal Clinical Study of Electroconvulsive Therapy and Magnetic Seizure Therapy
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
Multi-Omic, Clinomic and Digitomic Attributes of Major Depression for Integrative Analytics
Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neuromodulation in Depression
Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
A Study of Adjunctive Aripiprazole in Participants With Major Depressive Disorder